Ownership and insider activity for Seres Therapeutics, Inc. (MCRB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI).
Price
| Price | $4.21 |
| Market Cap | $41M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-15 | Brady Kelly | M-Exempt | 181 | |
| 2026-08-17 | Brady Kelly | S-Sale | 64 | $291 |
| 2026-08-15 | Brady Kelly | M-Exempt | 91 | |
| 2026-08-15 | Brady Kelly | M-Exempt | 90 | |
| 2026-08-15 | Shaff Eric D. | M-Exempt | 722 | |
| 2026-08-17 | Shaff Eric D. | S-Sale | 263 | $1K |
| 2026-08-15 | Shaff Eric D. | M-Exempt | 332 | |
| 2026-08-15 | Shaff Eric D. | M-Exempt | 390 | |
| 2026-08-15 | Henn Matthew R | M-Exempt | 238 | |
| 2026-08-17 | Henn Matthew R | S-Sale | 81 | $369 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54.5M | $36.1M | $85.8M | $65.1M | $116.0M | $180.0M | $163.0M | $128.0M | $30.8M | $45.8M |
| Short-term Investments | $138.7M | $113.9M | 0 | $29.7M | $137.6M | $110.7M | $18.3M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $1.8M | $9.4M | 0 | 0 | 0 | $4.8M | $360000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $29.6M | 0 | 0 |
| Total Current Assets | $198.4M | $155.1M | $92.7M | $100.2M | $268.8M | $303.6M | $194.8M | $175.4M | $38.7M | $49.4M |
| Property, Plant & Equipment | $36.1M | $32.9M | $26.3M | $30.9M | $22.9M | $36.1M | $134.0M | $108.0M | $92.4M | $80.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $272.6M | $189.5M | $120.5M | $132.4M | $342.9M | $354.9M | $348.8M | $358.6M | $139.8M | $138.2M |
| Accounts Payable | $7.6M | $7.0M | $6.4M | $4.9M | $4.0M | $13.7M | $17.4M | $3.6M | $4.1M | $1.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | $454000 | 0 | $456000 | 0 | 0 | $10.4M |
| Total Current Liabilities | $30.5M | $31.6M | $42.0M | $46.0M | $46.4M | $82.3M | $85.6M | $98.7M | $41.2M | $19.3M |
| Long-term Debt | 0 | 0 | 0 | $24.6M | $24.6M | $24.6M | $50.6M | $101.5M | 0 | 0 |
| Total Liabilities | $140.0M | $128.8M | $168.5M | $180.8M | $168.2M | $223.4M | $338.0M | $403.5M | $126.0M | $94.0M |
| Retained Earnings | -$174.2M | -$263.6M | -$389.4M | -$459.6M | -$548.8M | -$614.4M | -$864.5M | -$978.2M | -$978.1M | -$972.4M |
| Total Equity | $132.6M | $60.7M | -$48.0M | -$48.3M | $174.8M | $131.5M | $10.8M | -$44.9M | $13.8M | $44.2M |
| Total Debt | $10.7M | $9.0M | $7.2M | $44.8M | $40.8M | $49.2M | $162.6M | $198.8M | $91.6M | $83.0M |
| Net Debt | -$182.5M | -$141.0M | -$78.6M | -$50.0M | -$212.8M | -$241.5M | -$18.8M | $70.8M | $60.8M | $37.2M |
| Working Capital | $167.9M | $123.5M | $50.6M | $54.2M | $222.4M | $221.4M | $109.2M | $76.8M | -$2.5M | $30.1M |
Financial Health
| Debt / Equity | 1.64 |
| Current Ratio | 2.11 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -10.99 |
Profitability
| Return on Equity | -60.32% |
| Return on Invested Capital | -89.99% |
| Return on Assets | -22.11% |
| Gross Margin | 82.58% |
| Operating Margin | -4462.77% |
| Net Margin | -1192.94% |
Related companies: ABOS · ACTU · APLT · CGTX · HURA · INO · IRD
Explore sector: Healthcare · Biotechnology
More sections of MCRB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks